Biotech Values

[dewophile]

They weren’t targeting the prefusion protein like the other players but the lower efficacy against severe disease is still surprising I think. JNJ dropping out was probably more unexpected but both had seemingly strong phase 2 data
Looks like the pot will be split 3 ways for the foreseeable future